Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,416.00+0.10%ETH$2,442.29+0.95%GOLD$4,397.70-0.05%OIL$100.86-1.03%
Smart Investors Daily
DR

NASDAQ · DRTSW

Alpha Tau Medical Ltd.

Healthcare · Biotechnology

$4.37

Up+$0.21 (+5.05%)

Updated Sep 18, 2026, 8:48 AM

SID Score

5.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
31.51M
P/E ratio
-10.28
Dividend yield
0.00%
52-week range
$0.72 – $4.29
Volume
210.59K
Avg. volume
15.87K

Price performance

DRTSW price history

1M range · 20 trading sessions · Daily adjusted prices

DRTSW closed at $4.37 after 20 trading sessions, up 13.51% for the selected period.

Last close
$4.37
Period change
+13.51%
Period low
$3.45
Period high
$4.37
Daily close
View OHLC price history
DRTSW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 17, 2026$4.09$4.62$4.00$4.37210.59K
Sep 16, 2026$4.12$4.165$3.85$4.16123.48K
Sep 15, 2026$3.72$4.10$3.56$4.04154.95K
Sep 14, 2026$3.74$4.02$3.7201$3.740123.21K
Sep 11, 2026$4.07$4.07$3.70$3.839917.24K
Sep 10, 2026$3.81$4.19$3.67$4.0045.8K
Sep 9, 2026$4.08$4.11$3.695$3.829944.98K
Sep 8, 2026$4.29$4.29$3.96$4.2346.21K
Sep 4, 2026$3.855$4.28$3.855$4.1746.1K
Sep 3, 2026$3.85$4.29$3.83$3.9274.14K
Sep 2, 2026$3.58$3.83$3.46$3.7629.91K
Sep 1, 2026$3.36$3.75$3.20$3.4559.28K
Aug 31, 2026$3.79$3.92$3.60$3.6017.43K
Aug 28, 2026$4.03$4.03$3.70$3.7977.2K
Aug 27, 2026$4.1101$4.17$4.00$4.0040.35K
Aug 26, 2026$3.83$4.18$3.80$4.1071.54K
Aug 25, 2026$4.00$4.10$3.75$3.89144.93K
Aug 24, 2026$4.2156$4.25$3.84$4.0059.94K
Aug 21, 2026$3.80$4.25$3.80$4.24112.85K
Aug 20, 2026$3.68$3.90$3.67$3.8519.04K

Latest DRTSW news

The latest Smart Investors Daily articles mentioning DRTSW.

Stock researchCompany · Overview

DRTSW research

Overview

Company profile and research snapshot.

Company profile

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

- IMPACT, a multicenter pilot study of Alpha DaRT® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total of 48 treated patients, driven by overwhelming demand from patients and clinicians - - Alpha DaRT is delivered as a one-time add-on alongside standard first-line chemotherapy, an approach supported by the favorable safety profile observed in the earlier Israeli and Canadian studie

Yahoo · Aug 28, 2026

ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness

By M. Marin NASDAQ: ORMP READ THE FULL ORMP RESEARCH REPORT Gains on investment portfolio + service agreement income contributed to 2Q26 EPS of $2.76 Oramed Pharmaceuticals (NASDAQ: ORMP) leverages its strong balance sheet, with $15.2 million of cash and equivalents and $50.6 million of cash and equivalents plus short-term investments, to allocate capital to investments in the biomedical and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By